Transcriptomic changes underlying EGFR inhibitor resistance in ...

The goals of this study were to identify transcriptomic changes that arise in basal-like breast cancer cells during the development of ...

(PDF) Transcriptomic changes underlying EGFR inhibitor resistance ...

The goals of this study were to identify transcriptomic changes that arise in basal-like breast cancer cells during the development of resistance to ...

Transcriptomic changes underlying EGFR inhibitor resistance in human and mouse models of basal-like breast cancer. Rashid, Narmeen S; Boyd, David C; Olex, ...

GSE189324 - GEO Accession viewer

Aim: The goals of this study were to identify transcriptomic changes that arise in basal-like breast cancer cells during the development of ...

Single cell lineage tracing reveals clonal dynamics of anti-EGFR ...

To elucidate the underlying mechanisms of this variability, we employ cellular barcoding and single-cell transcriptomics to reconstruct the ...

Transcriptomic Heterogeneity of EGFR-Mutant Non–Small Cell Lung ...

Notably, dynamic alterations in transcripts, including neuroendocrine genes, are observed even in the EGFR tyrosine kinase inhibitor–naïve ...

Genomic and Transcriptomic Determinants of Therapy Resistance ...

Sixty-four percent of biopsies with acquired resistance harbored no genetic resistance drivers. Most of these had switched from a cetuximab-sensitive ...

Single-cell transcriptome analysis revealed a suppressive tumor ...

Backgrounds Immunotherapy is less effective in patients with epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC).

Integrative transcriptome analysis reveals the molecular events ...

reasons underlying the poor response of EGFR-mutant (EGFR-MU) LUADs to immunotherapy with PD-1/PD-L1 inhibitors are unknown. Utilizing ...

Genomic and transcriptomic determinants of therapy resistance and ...

We applied genomic and transcriptomic analyses to biopsies from 35 RAS wild-type CRCs treated with the anti-EGFR-Ab cetuximab in a prospective ...

Resistance to anti-EGFR therapies in metastatic colorectal cancer

Recently, metabolic remodelling, CSCs and EMT have also been confirmed to promote resistance to targeted therapy (Fig. 1). Accordingly, ...

Transcriptome analysis of EGFR tyrosine kinase inhibitors ...

However, most of the patients who are initially responsive to EGFR TKIs with activating EGFR mutations eventually develop acquired resistance after long-term ...

Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors - MDPI

Unfortunately, despite initial efficacy, nearly all treated patients evolve drug resistance due to the emergence of either new mutations or rewired signaling ...

Integrative transcriptomic analysis identifies emetine as a promising ...

EGFR-mutant lung cancer, for instance, also undergoes significant transcriptomic changes during the development of resistance to EGFR inhibitors ...

Transcription factor ZNF263 enhances EGFR - Cell Press

To assess transcriptome changes occurring during osimerti- nib exposure, RNA sequencing (RNA-seq) was performed and interrogated in the PC-9, ...

EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired ...

Invadopodia formation is regulated by EGF and other growth factors, as well as signals from the extracellular matrix [138,139]. The mechanism underlying ...

Single-Cell RNA sequencing identified subpopulations that mediate...

The goals of this study were to identify transcriptomic changes that arise in basal-like breast cancer cells during the development of resistance to epidermal ...

In silico transcriptome screens identify epidermal growth factor ...

Our results underscore the potential for in silico transcriptome-based drug screening in diseases lacking efficient models and suggest EGFR ...

Known and putative mechanisms of resistance to EGFR targeted ...

As first-line treatments, EGFR inhibitors have been shown to produce overall response rates (ORRs) of close to 75% in patients who harbor activating mutations ...